

*To the Copenhagen Stock Exchange  
and the Press*

Release no. 8/2007

### **Report regarding the managements' and closely related parties' transactions with securities in Pharmexa A/S**

Pursuant to section 28a of the Danish Securities Trading Act, Pharmexa is required to publish the managements' and their closely related parties' transactions with shares and related securities in Pharmexa.

|   |                           |
|---|---------------------------|
| Name                                      | Peter Nordkild            |
| Position:                                 | Chief Commercial Officer  |
| Security Code (ISIN-code):                | DK0015966592              |
| Name of the securities:                   | Share                     |
| Type of transaction:                      | Buy                       |
| Date of trade:                            | 08.03.2007                |
| Place of transaction:                     | Copenhagen Stock Exchange |
| Traded securities (no.):                  | 17,500                    |
| Market value in DKK of traded securities: | 283,000                   |

Hørsholm, March 9, 2007

Jakob Schmidt  
Chief Executive Officer

#### **Additional information:**

Jakob Schmidt, Chief Executive Officer, telephone +45 4516 2525

Claude Mikkelsen, Head of Investor Relations, telephone +45 4516 2525 or +45 4060 2558

**Note to editors:** Pharmexa A/S is a leading company in the field of active immunotherapy and vaccines for the treatment of cancer, serious chronic and infectious diseases. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer, rheumatoid arthritis, bone degeneration and Alzheimer's disease, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Its leading programs are GV1001, a peptide vaccine that has entered phase III trials in pancreatic cancer and phase II trials in liver cancer, and HIV and hepatitis vaccines in phase I/II. Collaborative agreements include H. Lundbeck, Innogenetics, IDM Pharma, ImmunoVaccine Technologies and Bavarian Nordic. With operations in Denmark, Norway and USA, Pharmexa employs approximately 100 people and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.